Matrix metalloproteinases (MMPs) degrade extracellular matrix; MMP activity, particularly of MMP-9, is elevated in the white matter in multiple sclerosis (MS) patients. The cerebral cortical extracellular matrix includes perineuronal nets (PNs) that surround parvalbuminpositive neurons (PV-positive neurons) and are important for their function. We measured active and total MMP-9 levels in postmortem homogenates of demyelinated and nondemyelinated cerebral cortical regions from 9 MS and 7 control cases and assessed Wisteria floribunda agglutin (WFA)-positive PNs in paraffin sections from 15 MS and 6 controls and PV-positive neurons in sections from 26 MS and 6 controls. Active MMP-9 levels were higher in demyelinated than in nondemyelinated or control cortex ( p G 0.05). The area fraction positive for WFA was lower in demyelinated than nondemyelinated MS or control cortex; the latter difference was significant ( p G 0.05). Most PV-positive neurons in demyelinated but not intact cortex lacked a PN, and some showed perikaryal phosphorylated neurofilament protein accumulation. Loss of WFA-labeled PNs was not associated with reduced PV-positive neurons numbers. Thus, elevated MMP-9 in cortical plaques is associated with loss of PNs; PVpositive neurons are preserved but show abnormal neurofilament accumulations. Matrix metalloproteinase-mediated degradation of PNs in cortical plaques may, therefore, contribute to neuronal dysfunction and degeneration in MS patients.
INTRODUCTION
Matrix metalloproteinases (MMPs) are zinc-requiring, calcium-dependent endopeptidases that mediate the degradation of protein components of the extracellular matrix (ECM) (1) . Several MMPs are produced by neurons and glia and are thought to be involved in the turnover and remodeling of ECM in the central nervous system.
The specialized ECM that forms around certain neurons constitutes a structure known as the perineuronal net (PN). This surrounds neuronal cell bodies, proximal dendrites, and initial axon segments (2, 3) and consists of polyanionic chondroitin sulfate proteoglycans (CSPGs) and associated molecules such as hyaluronic acid and tenascins. Perineuronal nets are implicated in synaptic stabilization and plasticity (4Y7), ion homeostasis around highly active neurons (8Y13), and neuroprotection (14Y16). Several studies have also indicated that the PN are important for memory and learning (17Y20). Perineuronal nets in the cerebral cortex are particularly associated with GABAergic interneurons (21Y24), most of which express the calcium-binding protein parvalbumin (PV) (25Y27), but PNs also surround pyramidal neurons.
The level of several MMPs is increased in the white matter in multiple sclerosis (MS) (28Y30), that of MMP-9 in particular. Matrix metalloproteinase-9 levels (including those of the active protease) are also increased in the serum and cerebrospinal fluid in MS, particularly in patients with active disease (31Y35).
In the present study, we investigated MMP-9 levels in the cerebral cortex in MS and whether the effects increases in these levels might have on PNs and the neurons they surround. We found that cortical demyelination is accompanied by elevated MMP-9 activity, degradation of PNs, and swelling and accumulation of phosphorylated neurofilament protein in the PV-positive neurons that PNs normally surround. The degradation of perineuronal ECM by MMP-9 activity in cortical plaques may, therefore, contribute to neuronal dysfunction and damage in MS.
MATERIALS AND METHODS

Brain Tissue
Tissue samples for this study were obtained from the UK Multiple Sclerosis Tissue Bank, Imperial College, London, and from Frenchay Neuropathology Department archives. The research was approved by Frenchay Research Ethics Committee. Frozen tissue samples from multiple regions of cerebral cortex and white matter were available from 9 cases of neuropathologically confirmed MS and 7 controls (Table 1 ). The tissue had been snap-frozen by immersion in isopentane and stored at j80-C. Paraffin blocks of formalin-fixed tissue from multiple regions of cerebral cortex were available from 24 cases of neuropathologically confirmed MS and 7 controls (Table 1) .
Immunoperoxidase Labeling of Paraffin Sections
Seven-micrometer-thick sections were cut from blocks of the frontal and temporal lobes. The sections were immunostained with antibodies to myelin basic protein (MBP) and PV; sections from selected blocks were also stained with an antibody to MMP-9 ( To determine whether MMP-9 staining was specific, an adsorption control was also used. The antibody was preincubated overnight with a 1,000-molar excess of recombinant MMP-9 (R&D systems, Abingdon, UK) at 4-C before incubation with a tissue section followed by immunostaining as above.
Quantitative Assessment of WFA and PV in Paraffin Sections
Histometrix software (Kinetic Imaging, Nottingham, UK), driving a Leica DM microscope with a motorized stage, was used to quantify WFA and PV immunolabeling. Areas of demyelinated and nondemyelinated cortex were outlined interactively, and the software was programmed to make an automated unbiased selection of 10 random Â20 objective fields (covering a total of 4 mm 2 ) within the outlined area. Every nondemyelinated area was outlined in a region of cortex that was of approximately the same size, shape, and intracortical location as an outlined demyelinated area in the same section. All of the demyelinated and corresponding nondemyelinated areas analyzed were 94 mm 2 (i.e. they exceeded the area sampled by the software). The captured images were interactively edited to exclude blood vessels. The mean percentage area of brain parenchyma that was immunopositive for WFA was determined for each area of demyelinated cortex and the paired area of nondemyelinated cortex. Counts were then made of neurons in the sampled fields that were immunopositive for PV, and their mean number per centimeter squared was calculated. In sections from a few blocks, WFA did not label any structures either within or outside the plaques. To avoid skewing the results by possible technical factors (perhaps reflecting postmortem changes), we excluded these sections from the analysis. The number of blocks analyzed in each group is shown in the Results section.
Double Immunofluorescent Labeling of Paraffin Sections
Sections were dewaxed, hydrated, and rinsed, as above. To reduce autofluorescence, the sections were incubated in 5 mM of copper sulfate and 50 mM of ammonium acetate for 1 hour at room temperature before microwaving in sodium citrate buffer (0.01 M, pH 6.0, 5 minutes). The distribution of MMP-9 was assessed by double immunofluorescence using rabbit anti-MMP-9 antiserum in combination with antibodies to MBP, microtubule-associated protein 2, glial fibrillary acidic protein, HLA-DR, CD45RO, and CD34 ( Table 2) . Evidence of neurodegenerative change in PV-positive neurons was assessed by double immunofluorescence using rabbit anti-PV antiserum in combination with an antibody to phosphorylated neurofilament protein. Nonspecific binding was blocked with 10% normal goat serum diluted in PBS containing 0.1% Triton X-100. Sections were incubated at 4-C overnight with primary antibodies. Sections were then washed in PBS and incubated for 30 minutes in the dark with the appropriate secondary antibodies (1:2000): goat anti-rabbit Alexa Fluor 555, goat anti-mouse Alexa Fluor 488, and goat anti-rat Alexa Fluor 488 (all from Invitrogen, Paisley, UK), before being washed in PBS and mounted in Vectashield medium containing the nuclear dye 4 ¶6 ¶-diamidino-2-phenylindole (H-1200; Vector Laboratories). Immunofluorescence images were acquired using an inverted Leica CTR 6000 fluorescence microscope and merged with Leica Application Suite Advanced Fluorescence software (Leica UK, Milton Keynes, UK).
Combined Immunofluorescent and Lectin Histochemical Labeling
As described above, sections were dewaxed, hydrated, incubated in 5 mM of copper sulfate and 50 mM of ammonium acetate for 1 hour at room temperature and microwaved in sodium citrate buffer. The distribution of PN in relation to PV-positive neurons was assessed by double labeling using biotinylated WFA in combination with antibody to PV. Nonspecific binding was blocked with 20% normal goat serum in PBS containing 0.1% Triton. Sections were incubated at 4-C overnight with rabbit anti-PV, washed in PBS, and incubated for 30 minutes in the dark with fluorescein avidin D (1:100) (A-2001; Vector Laboratories), goat anti-rabbit Alexa Fluor 555 before being washed in PBS, and mounted in Vectashield medium containing 4 ¶6 ¶-diamidino-2-phenylindole.
Assessment of Demyelination in Blocks of Frozen Tissue
Sections 15 Km in thickness were cut from the blocks of frozen tissue (each measuring approximately 2 Â 2 cm in cross-section and 1 cm in thickness) and immunostained for MBP. The sections were fixed in acetone, immersed in icecold methanol, rinsed, immersed in 3% hydrogen peroxide in methanol for 30 minutes to block endogenous peroxidase, and rinsed in PBS. Nonspecific binding was blocked by incubation for 20 minutes in Vectastain blocking serum. Sections were incubated for 1 hour at room temperature with anti-MBP antibody ( Table 2) . The sections were then rinsed in PBS before incubation for 20 minutes with Vectastain Biotinylated Universal antibody and 20 minutes with VectaElite ABC Complex, followed by 10-minute incubation with DAB and 0.01% H 2 O 2 . Sections were washed in water, immersed in copper sulfate DAB enhancer, counterstained with hematoxylin, dehydrated, cleared, and mounted.
Measurement of MMP-9 Activity in Cerebral Cortex
After the sections had been cut and used to assess the distribution of cortical demyelination, the frozen tissue blocks were thawed on ice and the leukocortical junction was identified macroscopically. The meninges were removed, and the cortex was carefully dissected from underlying white matter to ensure that the homogenates were prepared entirely from the cortex. The cortex was homogenized on ice in a ratio of 300 mg of tissue to 1 ml of lysis buffer (0.1 M NaCl, 0.01 M Tris (pH 7.6), 100 KM phenylmethylsulfonylfluoride, 1 Kg/ml aprotinin, and 1% sodium dodecyl sulfate in distilled water). The supernatants were collected and protein concentrations determined using the Sigma total protein kit (TP0100 Sigma, Dorset, UK). The supernatants were stored at j80-C until required. Matrix metalloproteinase-9 activity assays (Biotrak activity assay system; Amersham Biosciences, Buckinghamshire, UK) were used to measure total and acztive MMP-9. Homogenates were diluted to 3 mg/ml in assay buffer and assays performed according to the manufacturer's instructions. The blank (assay buffer only) standards (MMP-9, 0.5Y16 ng/ml) were all assayed in duplicate. Ninety-six well plates coated with MMP-9 antibody were incubated with the standards or samples overnight at 2 to 8-C. 4-Aminophenylmercuric acetate was added to the standards to activate the MMP-9 in the samples in which total MMP-9 was to be measured. The detection reagent (detection enzyme plus substrate) was added, and the plates were incubated at 37-C for 1 hour. Activation of the prodetection enzyme by bound active MMP results in the cleavage of the chromogenic substrate. The resultant color (at 405 nm) is proportional to the concentration of active MMP, which was determined by interpolation from the standard curve.
Each assay was performed in duplicate, and assays on multiple samples of cortex were performed in most cases from each patient. The exact number varied from case to case because some yielded a higher proportion of samples with cortical demyelination than others; from each MS patient studied, we were able to analyze at least 1 demyelinated and 1 nondemyelinated sample; from some, we analyzed as many as 6 of 1 or both types of cortex samples. For each case, we then calculated the mean values for total and active MMP-9 in demyelinated cortex and in nondemyelinated cortex and FIGURE 1. Levels of active and total matrix metalloproteinase-9 (MMP-9) in control, nondemyelinated, and demyelinated multiple sclerosis (MS) cortex. The overall mean values T SE are shown for 9 patients with MS (14 samples of nondemyelinated and 31 of demyelinated MS cortex) and 7 controls (17 samples of cortex). Active MMP-9 levels were significantly higher in demyelinated than nondemyelinated (p G 0.01) or control cortex ( p G 0.05). Total MMP-9 levels did not differ significantly between demyelinated, nondemyelinated, and control cortex. used these values for the subsequent statistical comparisons. Similarly, the mean total and active MMP-9 values were determined for each control and those mean values used for statistical comparisons.
Measurement of Myeloperoxidase Activity in Cerebral Cortex
Measurement of myeloperoxidase (MPO) activity in homogenates from the blocks of cortex had been assayed as part of a previous study (36) using an MPO immunocapture-based peroxidase assay (Innozyme Myeloperoxidase Activity kits; Calbiochem, Merck Chemicals, Nottingham, UK).
Statistical Analysis
Paired t-tests were used to compare MMP-9 levels between demyelinated and nondemyelinated MS cortex from the same cases and the extent of WFA labeling of PNs and the number of PV-positive neurons/cm 2 between cortical plaques and matched areas of nondemyelinated cortex in the same sections. One-way analysis of variance (ANOVA) with Newman-Keuls posttests to compare the MMP-9 levels, WFA labeling, and numbers of PV-positive neurons/cm 2 in demyelinated and nondemyelinated MS cortex with those in control brains. Pearson correlation analysis was used to analyze the relationship between MPO activity and both active and total MMP-9 levels. For all tests, values of p G 0.05 were considered statistically significant.
RESULTS
MMP-9 Levels
Levels of active and total MMP-9 were measured in homogenates prepared from 9 MS cases (31 demyelinated and 14 nondemyelinated cortical samples) and 7 control cases (17 cortical samples). The difference in levels of active MMP-9 between MS and control cortex was significant (p = 0.0043, 1-way ANOVA). Posttesting indicated that active MMP-9 levels were significantly greater in demyelinated (mean T SE = 0.72 T 0.09 ng/ml) than nondemyelinated (0.42 T 0.06 ng/ml; p G 0.01) or control cortex (0.44 T 0.09; p G 0.05; Fig. 1 ). Active MMP-9 levels did not differ significantly between control and nondemyelinated MS cortex. The difference in active MMP-9 levels between demyelinated and nondemyelinated cortex was confirmed by paired t-test (p = 0.016).
Total MMP-9 levels ( Fig. 1) did not differ significantly among demyelinated (mean T SE = 7.73 T 1.60 ng/ml), nondemyelinated (6.34 T 1.73 ng/ml), or control (5.06 T 1.44 ng/ml) cortex ( p = 0.63, 1-way ANOVA).
We previously reported that cortical plaques had significantly elevated MPO levels and that MPO was expressed by CD68-immunopositive microglia within the demyelinated cortex (36) . Measurement of MPO, therefore, provides a way of assessing demyelinating activity within homogenates of cerebral cortex. Comparison of MMP-9 levels with those of MPO activity revealed a highly significant correlation (p G 0.0001) between MPO and both active and total MMP-9 ( Figs. 2A, B) .
Distribution of Pro-MMP-9/MMP-9 in MS Cortex
The MMP-9 antibody used does not distinguish between the proenzyme and the active form; it labeled most neurons in a diffuse cytoplasmic pattern (Figs. 3A, B) . In keeping with a previous report (30) , macrophages in regions of demyelination in the white matter were MMP-9-positive; however, unlike Maeda and Sobel, we did not see labeling of ramified microglia (data not shown). Preadsorption with recombinant MMP-9 abolished the labeling, thereby demonstrating the specificity of the antibody used (Fig. 3C vs D) . Double immunofluorescent labeling for MMP-9 and microtubuleassociated protein 2 (Figs. 2EYH) confirmed the neuronal identity of the MMP-9-positive cells, both within and outside the plaques. Matrix metalloproteinase-9 did not colocalize with the microglial marker HLA-DR (Figs. 3IYL) . Combined labeling for MMP-9 and MBP confirmed that neurons were immunopositive for MMP-9 both within and outside cortical plaques (Figs. 3MYP) . Double immunofluorescence demonstrated that the MMP-9-positive cells were not astrocytes, as indicated by their lack of glial fibrillary acidic protein staining (Figs. 3RYU) . Matrix metalloproteinase-9 did not colocalize with either CD34, expressed by endothelial cells, or CD45RO, expressed by T cells (data not shown).
Distribution of PV-Positive Neurons and PN in Cerebral Cortex
Antibody to PV labeled scattered, mostly small cortical neurons. In MS brain samples, PV-positive neurons were distributed throughout the cortex, including within plaques (Figs. 4AYD) . In serial sections through the same cortical plaques, WFA labeling was largely confined to blood vessels and did not surround any neurons. In contrast, in serial sections through control cortex and nondemyelinated MS cortex, the distribution of neurons with strongly labeled PNs was similar to that of the PV-positive neurons (Figs. 4EYH) .
Quantitation of WFA Binding and PV Immunolabeling
Wisteria floribunda agglutin labeling was variable but was significantly lower within plaques (mean percentage area labeled T SE = 1.22 T 0.34; n = 21, from 15 MS cases) than in matched nondemyelinated areas of cortex in the same sections (2.29 T 0.76; p = 0.01, paired t-test on data transformed logarithmically for normalization). Comparison of both sets of values (from demyelinated and nondemyelinated MS cortex) with measurements on sections from control cortex (3.57 T 0.81; n = 13 from 6 control cases) indicated that WFA labeling differed significantly between the 3 groups (p = 0.001, 1-way ANOVA on log-transformed data). Posttesting indicated that there was significantly less WFA labeling in demyelinated cortex MS (p G 0.001) and nondemyelinated MS (p G 0.05) cortex compared with control cortex but not a significant difference between nondemyelinated and control cortex (p 9 0.05; Fig. 5 ).
The number of PV-positive neurons/cm 2 did not differ significantly between plaques (mean T SD, 92.71 T 11.21; n = 36, from 26 MS cases) and matched nondemyelinated areas of cortex in the same sections (98.06 T 9.91; p 9 0.5). Counts of PV-positive neurons in control cortex (n = 20 from 6 control cases) were higher (127.1 T 17.35/cm 2 ) than in demyelinated or nondemyelinated MS cortex, but the difference was not significant (p = 0.17, 1-way ANOVA on raw data; p = 0.34, 1-way ANOVA on log-transformed data; Fig. 5 ). The significant loss of PN in demyelinated compared with nondemyelinated or normal control cortex was not therefore simply due to degeneration of PV-positive neurons.
Lectin Histochemical and Immunofluorescent Labeling of PV-Positive Neurons
In control cortex, most PV-positive neurons were surrounded by a PN that was strongly labeled with WFA (Figs. 6AYD) . Similarly, most PV-positive neurons in nondemyelinated MS cortex were surrounded by a PN that was strongly labeled with WFA ( Figs. 6EYH) . At high magnification, the WFA labeling could be seen to enclose the neuronal somata and to extend for a considerable distance along the dendrites (Figs. 6IYL) . In demyelinated cortex, there was obvious loss of PN from around many PV-positive neurons and some of the WFA labeling that remained appeared weak ( Figs. 6MYT) .
Further immunolabeling revealed abnormal perikaryal accumulation of phosphorylated neurofilament protein in scattered neurons within cortical plaques but only rarely in nondemyelinated cortex. Many of the neurons with perikaryal accumulation of phosphorylated neurofilament protein were also immunopositive for PV (Figs. 6UYBB) .
DISCUSSION
In this study, we have demonstrated that regions of cortical demyelination in MS brains are associated with significantly elevated levels of both the proenzyme and active forms of MMP-9 and with reduced amounts of WFA-positive PN. We also provide evidence suggesting that the loss of PN may be deleterious for the neuron, as evidenced by the perikaryal accumulation of phosphorylated neurofilament protein.
Many previous studies have demonstrated upregulation of MMP-9 in brain tissue, serum, and cerebrospinal fluid of patients with MS (28, 29, 31Y35, 37Y41), particularly during clinical exacerbations of disease. Immunohistochemical studies have revealed that MMP-9 is present in macrophages, microglia, and astrocytes in white-matter MS lesions (28Y30). Our present immunohistochemical findings suggest that neurons are the main source of proYMMP-9/MMP-9 in the cerebral cortex, a finding consistent with several previous studies (42Y46).
The factors that regulate neuronal production of proYMMP-9 are still unclear and may include cytokines or MMPs derived from astrocytes, microglia, or lymphocytes in the overlying leptomeninges. Of note was the close correlation that we observed between MPO levels and both total and active MMP-9 levels. Upregulation of neuronal MMP-9 expression has been observed in response to various forms of neuronal injury (47, 48) . It is also possible that the release of glutamate by activated microglia (49) may upregulate neuronal production of MMP-9 through activation of neuronal glutamate receptors (50) . Several proteases have been shown to activate proYMMP-9, including MMP-2 (51) and MMP-3 (52Y54), which are expressed by astrocytes and microglia (30, 46, 55, 56) . The activation of microglia, which we (36) and other groups (57, 58) have reported to be a feature of cortical demyelination, may therefore contribute to the generation of active MMP-9 from the neuronally produced proenzyme. Furthermore, cleavage and activation of secreted proYMMP-9 can be initiated by superoxide anions such as HOCl (59) , which are likely to be present in cortical plaques as a result of MPO activity (36) .
In 1999, Gutowski et al (60) reported a significant loss of tenascin-R immunoreactivity within regions of acute white-matter demyelination in MS brain. Tenascin-R is required for assembly of ECM molecules in the PN, and mice deficient in this glycoprotein have poorly defined PNs that lack or have reduced levels of some CSPGs (17) . In the present study, we identified substantial loss of at least the CSPG-acetylgalactosamine component of the PN from regions of demyelination in MS cortex. This was not secondary to the degeneration of PV-positive neurons because their numbers were relatively preserved. It remains possible that some loss of PN labeling resulted from loss of other neuronal populations in the cortex, such as pyramidal neurons, many of which are also surrounded by a PN, although this is generally less abundant than that around PV-positive interneurons.
Preservation of the number of PV-positive neurons does not necessarily signify preservation of their function. The abnormal perikaryal accumulation of phosphorylated neurofilaments in some of these neurons strongly suggests damage to the axon if not the cell body (61) , and indeed, transection of axons has been reported to be relatively common in cortical plaques (58) . Although the loss of PN could be a direct consequence of MMP-9 activity, it is also conceivable that PN degradation could be initiated by axonal damage, with secondary activation of cortical microglia around the nerve cell body, as has been demonstrated in studies after experimental transection of the facial nerve (62, 63) .
Whatever the mechanisms of degradation of perineuronal ECM in cortical plaques, it seems likely that the consequences will be deleterious for the nerve cells, with potential adverse effects on synaptic plasticity (4Y7), ion homeostasis (8Y13), and neuroprotection (14Y16). Further studies will be needed to establish the extent to which these abnormalities contribute to neuronal dysfunction in MS patients and the ways in which this might be prevented.
